HRs for Effectiveness and Safety Outcomes in the IPTW Cohorts
The annual rates and HRs for the primary analyses of the safety and effectiveness composites in the IPTW treatment groups in an on-treatment are shown in Supplementary Table S11 and Figure 4 (HRs only). With warfarin as the reference group, rivaroxaban 15 mg and 20 mg were associated with a similar effectiveness composite (HR 0.84; 95% CI 0.60–1.18 and HR 0.83; 95% CI 0.61–1.13, respectively); and similar safety profile (HR 1.13; 95% CI 0.70–1.83 and HR 1.29; 95% CI 0.84–1.95, respectively). Apixaban 2.5 mg was associated with a similar effectiveness (HR 1.00; 95% CI 0.79–1.26), but better safety (HR 0.65; 95% CI 0.43–0.99) profile, while apixaban 5.0 mg was associated with a better effectiveness (HR 0.76; 95% CI 0.65–0.88), but a similar safety risk (HR 0.94; 95% CI 0.66–1.35) profile. The observed improvement in the effectiveness composite for apixaban 5.0 mg was driven by a reduction in mortality (HR 0.61; 95% CI 0.43–0.88).